Join to view full profile
333 Cottman AvePhiladelphia, PA 19111
Phone+1 215-728-6900
Fax+1 215-214-3779
Dr. Abbosh is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Washington University/B-JH/SLCH ConsortiumResidency, Urology, 2009 - 2013- Washington University/B-JH/SLCH ConsortiumResidency, Surgery, 2008 - 2009
Indiana University School of MedicineClass of 2008
Certifications & Licensure
PA State Medical License 2013 - 2026
MO State Medical License Active through 2013
American Board of Urology Urology
Publications & Presentations
PubMed
- Corrigendum to "P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9" [Neoplasi...Xiaobing Tian, Nagib Ahsan, Amriti Lulla, Avital Lev, Philip Abbosh
Neoplasia. 2026-10-01 - 1 citationsAssociation Between Antibiotic Therapy and Treatment Effectiveness in Patients With Renal Cell Carcinoma Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhi...Avery E Braun, Hamed Hesami, Mengying Deng, Jill S Hasler, Laura Bukavina
JCO Oncology Practice. 2026-04-29 - Gender Disparities in Citations and Altmetric Attention Score in Oncology.Rebecca A Campbell, Emma Helstrom, Lauren Chew, Renu Eapen, Elizabeth Plimack
JCO Oncology Practice. 2026-02-01
Journal Articles
- Genomic Copy Number Alterations in Renal Cell Carcinoma with Sarcomatoid FeaturesRichard E Greenberg, Rosalia Viterbo, Timothy Ito, Marc C Smaldone, Joseph R Testa, Philip H Abbosh, Robert G Uzzo, Alexander Kutikov, The Journal of Urology
Press Mentions
Chemotherapy May Harness Immune System in Bladder CaApril 13th, 2017
Grant Support
- Intratumor Heterogeneity as a Correlate of Clinical Outcome in Patients Avoiding Radical CystectomyRESEARCH INST OF FOX CHASE CAN CTR2026–2031
- Intratumor Heterogeneity as a Correlate of Clinical Outcome in Patients Avoiding Radical CystectomyRESEARCH INST OF FOX CHASE CAN CTR2026–2031
- Intratumor Heterogeneity as a Correlate of Clinical Outcome in Patients Avoiding Radical CystectomyRESEARCH INST OF FOX CHASE CAN CTR2026–2031
- Clinical Translation of a Urine-Based Biomarker for the Detection of Residual Disease in Radical Cystectomy CandidatesRESEARCH INST OF FOX CHASE CAN CTR2026–2028
- Optimization of urinary DNA deep sequencing tests to enhance clinical staging of bladder cancer patientsRESEARCH INST OF FOX CHASE CAN CTR2021–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
